Fixed dose combination (antiretroviral)
From Wikipedia, the free encyclopedia
Fixed dose combinations of antiretrovirals are multiple antiretroviral drugs combined into a single pill. They may combine different classes of antiretrovirals or contain only a single class. Licensed fixed dose combinations include:
Combivir®: zidovudine + lamivudine. The FDA approved it September 26, 1997. It is marketed by GlaxoSmithKline.
Trizivir®: abacavir + zidovudine + lamivudine. The FDA approved it November 15, 2000. It is marketed by GlaxoSmithKline.
Kaletra®: lopinavir (for its HIV protease enzyme inhibition) with ritonavir included to boost serum levels of lopinavir through inhibition of CYP3A4 (a liver enzyme that metabolizes many drugs). The FDA approved it September 15, 2000.
Epzicom® (U.S. name) or Kivexa® (European name): abacavir + lamivudine. The FDA approved it August 2, 2004 for once-a-day dosing. It is marketed by GlaxoSmithKline.
Truvada®: emtricitabine + tenofovir. The FDA approved it August 2, 2004 for once-a-day dosing. It is marketed by Gilead Sciences.
Atripla®: efavirenz + emtricitabine + tenofovir. The FDA approved it July 12, 2006. It is marketed by Gilead Sciences and Bristol-Myers Squibb in the U.S., and is not currently available elsewhere.
| Antivirals (primarily J05A, also S01AD and D06BB) edit | ||||
|---|---|---|---|---|
